Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Free cash flow
Bio-Techne Corp's free cash flow for fiscal 2026 was $263.2M, unchanged from fiscal 2025. Over the past ten years it has ranged from $119.5M (fiscal 2015) to $307.9M (fiscal 2021); the current reading is higher than 83% of that period. Free cash flow has risen for 3 consecutive fiscal years. Bio-Techne Corp ranks 16th of 611 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | $263.2M | 2.60% |
| FY2025 | $256.6M | 8.66% |
| FY2024 | $236.1M | 9.23% |
| FY2023 | $216.1M | (22.90%) |
| FY2022 | $280.4M | (8.93%) |
| FY2021 | $307.9M | 100.60% |
| FY2020 | $153.5M | (1.75%) |
| FY2019 | $156.2M | 4.53% |
| FY2018 | $149.4M | 16.25% |
| FY2017 | $128.5M | 1.01% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $86.9M | 12.07% |
| Mar 2026 | $77.6M | 1.42% |
| Dec 2025 | $76.5M | 244.21% |
| Sep 2025 | $22.2M | (76.19%) |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $724.8M |
| TECH Bio-Techne Corp | $263.2M |
| KRYS Krystal Biotech, Inc. compare | $257.8M |
| CORT Corcept Therapeutics Incorporated compare | $106.9M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$206.3M |
| IBRX ImmunityBio, Inc. compare | −$288.1M |
| BBIO BridgeBio Pharma, Inc. compare | −$435.4M |
| SMMT Summit Therapeutics PLC compare | −$459.8M |
| PCVX Vaxcyte, Inc. compare | −$894.1M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement